Opportunities in Biosimilars
With the approval of an abbreviated pathway by which biosimilars may be authorized in the US, the attention is now shifting to the challenges in store for innovator companies in defending their patents and the generics companies in challenging them. In this interview, Michael Kamarck, president of Merck BioVentures and senior vice president, vaccines and biologics manufacturing, discusses the opportunities and challenges in biosimilars.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.